Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental ...

Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Researchers believe this study further highlights that a key immune system switch warrants full investigation in MS and may ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

Breastfeeding for longer in infancy may be associated with lower disease severity and a later onset of MS in adulthood, a ...

Bernhard Hemmer, head of the Department of Neurology at the University Hospital of the Technical University Munich, explains: ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...